Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small glycanic drugs - Endotis

Drug Profile

Research programme: small glycanic drugs - Endotis

Alternative Names: EP 30; EP 31; EP 32; EP 33; EP 80061; EP8000; Small glycanic drugs research programme - Endotis

Latest Information Update: 03 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endotis Pharma
  • Class Oligosaccharides
  • Mechanism of Action Chemokine receptor antagonists; Intercellular signalling peptide and protein inhibitors; Interferon gamma inhibitors; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 02 Mar 2011 Preclinical development in Solid tumours is ongoing in France
  • 01 Jan 2011 Preclinical trials in Cancer in France (Parenteral)
  • 17 Apr 2010 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top